philboss 777
NEW YORK , Nov. 30, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of iLearningEngines, Inc. (NASDAQ: AILE) between April 22, 2024 and August 28, 2024 , both dates inclusive (the "Class Period"), of t the important December 6, 2024 lead plaintiff deadline. So what: If you purchased iLearningEngines securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the iLearningEngines class action, go to https://rosenlegal.com/submit-form/?case_id=28305 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 6, 2024 . A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) iLearningEngines' "Technology Partner" was an undisclosed related party; (2) iLearningEngines used its undisclosed related party Technology Partner to report "largely fake" revenue and expenses; (3) as a result of the foregoing, iLearningEngines significantly overstated its revenue; and (4) as a result of the foregoing, defendants' positive statements about iLearningEngines' business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the iLearningEngines class action, go to https://rosenlegal.com/submit-form/?case_id=28305 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com View original content to download multimedia: https://www.prnewswire.com/news-releases/aile-deadline-aile-investors-have-opportunity-to-lead-ilearningengines-inc-securities-fraud-lawsuit-302318967.html SOURCE THE ROSEN LAW FIRM, P. A.
Jazz Corner: Alternate Jazz Masterpieces – Part 1live Updated 1m ago Longhorns-Aggies rivalry returns Texas and Texas A&M are facing off for the first time since 2011. And the winner will head to the SEC Championship Game. Kickoff: 7:30 p.m. Where to watch: ABC. Streaming: Try Fubo for free. Latest odds: Texas, -6 . Subscribe to The Athletic on an exclusive offer here . Watch today’s game on Fubo and find the best ticket deals on StubHub . Find some consistency Texas' defense has been strong all season. It's second nationally in total defense and third in scoring defense. That's not the problem. The offense, however, has been inconsistent and sloppy. It's time for that to stop. The Longhorns need to find their rhythm on offense at the most important time of the season, especially on the road against their biggest rivals. Advertisement Run the ball, A&M The Aggies have to be able to run the ball. In all three of their losses against Notre Dame, South Carolina and Auburn, the Aggies had less than 170 yards rushing, including 146 against the Irish and 144 against the Gamecocks. Establish the run, limit the turnovers and let the rest of the offense open up from there. Ticket prices are as high as the stakes COLLEGE STATION, Texas — In the third quarter of Texas A&M’s blowout win against New Mexico State on Nov. 16, senior mechanical engineering student Ronaldo Resendiz left Kyle Field. Resendiz, a San Antonio native who will graduate in December, has attended most A&M home games in his four years on campus. With the Aggies’ eighth win of the season well in hand, he and a few friends ventured out for a quick meal so they could get back to the stadium as soon as possible — not for the end of the game, but to camp out for tickets to the home finale against hated rival Texas. Continue reading here. GO FURTHER The Texas-Texas A&M football rivalry is back, and the ticket prices are as high as the stakes By the numbers Passing offense: Texas 279.7 yards per game (17th nationally), Texas A&M 208.7 (86) Rushing offense: Texas 169.6 (58), Texas A&M 208.4 (17) Total offense: Texas 449.4 (18), Texas A&M 417.1 (44) Passing defense: Texas 143.5 (2), Texas A&M 227.7 (81) Rushing defense: Texas 104.0 (13), Texas A&M 128.4 (41) Total defense: Texas 247.5 (2), Texas A&M 356.1 (56) Scoring offense: Texas 36.5 points per game (15), Texas A&M 32.5 (36) Scoring defense: Texas 12.09 (3), Texas A&M 21.55 (T38) The coaches Steve Sarkisian is 35-15 in his fourth season as Texas' coach. He's 81-50 overall as a coach with stops at Washington and USC. Mike Elko is 8-3 in his first season as Texas A&M's coach. He is 24-12 overall as a coach with a stop at Duke. The series Texas leads 76-37-5 First meeting: Texas won 38-0 in 1894. Last meeting: Texas won 27-25 in 2011. Of note: The two programs faced off every year from 1915 to 2011.
Ireland's 22 help Nicholls State take down New Orleans 73-70
New York, USA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Neuroendocrine Tumors Market to Showcase Rapid Growth During the Study Period (2020–2034), at a CAGR of 5.1%| DelveInsight The launch of upcoming therapies such as ITM-11, CAM2029, RYZ101, CABOMETYX, ALPHAMEDIX, and others in the forecast period, rising incident population due to an increased number of endoscopic and radio-imaging studies, increasing research activities are driving neuroendocrine tumor market size. Companies such as Novartis, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda, and others are competing fiercely to capture the largest market sizes. DelveInsight’s latest Neuroendocrine Tumors Market Insights report includes a comprehensive understanding of current treatment practices, emerging neuroendocrine tumor drugs, market share of individual therapies, and current and forecasted neuroendocrine tumors market size from 2020 to 2034, segmented into 6MM [the United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom]. Key Takeaways from the Neuroendocrine Tumors Market Report According to DelveInsight’s analysis, the market size of neuroendocrine tumors in the US was USD 1.5 billion in 2023. In 2023, Somatostatin analogs (SSAs) captured the highest market size of approximately USD 700 million in the US, followed by LUTATHERA . However, by 2034, radioligand treatments including approved beta emitter-radioligand therapy [LUTATHERA], and most anticipated alpha emitter-based therapies are expected to drive the overall NETs market size. The total number of incident cases of NETs in the US was nearly 29,500 cases in 2023 and is projected to increase by 2034. Prominent emerging companies working in the domain of neuroendocrine tumors, including ITM Solucin GMBH , Camurus , Bristol Myers Squibb , Rayzebio , Exelixis , Ipsen , Takeda , Radiomedix , Orano Med , Perspective Therapeutics , Elicera Therapeutics , Chimerix , Enterome , Teclison , and others, are actively working on innovative neuroendocrine tumor drugs. These novel neuroendocrine tumor therapies are anticipated to enter the neuroendocrine tumors market in the forecast period and are expected to change the market. Some of the key emerging neuroendocrine tumor treatments include ITM-11 (N.C.A. 177LU-EDOTREOTIDE), CAM2029, RYZ101 (ACTINIUM-225 DOTATATE), CABOMETYX (Cabozantinib), ALPHAMEDIX (212PB-DOTAMTATE), [212PB] VMT- -NET , ELC-100 (ADVINCE), ONC201 , EO2401 + NIVOLUMAB , TIRAPAZAMINE (TEC-001) , and others. As the field of radioligand therapy evolves, there is an exciting shift towards alpha-emitting radioisotopes. At present, only beta-emitting radioisotopes are currently approved, companies are now focusing on developing alpha-emitters. In August 2024, Exelixis announced that its supplemental New Drug Application (sNDA) for CABOMETYX has been accepted in the US for: 1) the treatment of adults with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pancreatic neuroendocrine tumors (pNET), and 2) the treatment of adults with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated extra-pancreatic NET (epNET). The US Food and Drug Administration (FDA) assigned a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025. In July 2024 , Curium announced that it had submitted its 505(b)(2) NDA for Lutetium Lu 177 Dotatate Injection for the treatment of somatostatin receptor-positive (SSTR+) GEP-NETS. In April 2024, Novartis announced that the US FDA approved LUTATHERA for the treatment of pediatric patients 12 years and older with SSTR+ GEP-NETs, including foregut, midgut, and hindgut NETs. Discover which therapies are expected to grab the NETs market share @ Neuroendocrine Tumors Market Report Neuroendocrine Tumors Overview Neuroendocrine Tumors (NETs) are a diverse group of cancers that arise from neuroendocrine cells, which have characteristics of both nerve cells and hormone-producing cells. These tumors can develop anywhere in the body but are most commonly found in the gastrointestinal tract, pancreas, and lungs. The exact causes of neuroendocrine tumors are not fully understood, but certain factors may increase risk, including genetic syndromes like multiple endocrine neoplasia type 1 (MEN1), Von Hippel-Lindau disease, and neurofibromatosis. Other potential contributors include chronic inflammatory conditions, smoking, and exposure to certain chemicals. Symptoms of NETs can vary widely depending on the tumor's location and whether it secretes hormones. Some tumors may be asymptomatic for a long time. Common symptoms include abdominal pain, diarrhea, flushing of the skin, unexplained weight loss, and in cases of hormone-secreting tumors, symptoms related to excess hormones, such as changes in blood sugar levels or high blood pressure. Diagnosing NETs typically involves a combination of blood and urine tests to detect hormone levels, imaging studies like CT, MRI, or PET scans, and biopsies to analyze tumor tissue. Specialized tests like chromogranin A (CgA) blood tests or somatostatin receptor scintigraphy (Octreoscan) may also be used to identify neuroendocrine activity and locate tumors. Neuroendocrine Tumors Epidemiology Segmentation The neuroendocrine tumors epidemiology section provides insights into the historical and current neuroendocrine tumors patient pool and forecasted trends for the 6MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The neuroendocrine tumors market report proffers epidemiological analysis for the study period 2020–2034 in the 6MM segmented into: Total Incident Cases of NET Cases of NETs by Grade Stage-specific Cases of NET Cases of NETs by Site Cases of NETs by Functional Status Download the report to understand which factors are driving NETs epidemiology trends @ Neuroendocrine Tumors Epidemiological Insights Neuroendocrine Tumors Treatment Market Surgery is generally considered a first-line treatment for localized NETs. The frontline treatment for metastatic disease is somatostatin analogs, and currently, two agents are FDA-approved: SANDOSTATIN (octreotide acetate) and SOMATULINE DEPOT (lanreotide). Both somatostatin analogs provide symptomatic relief in 50% to 70% of patients and biochemical responses in 40% to 60% of patients. Traditionally, mTOR inhibitor – everolimus or sunitinib – was acknowledged as a second-line agent, but with the recent approval of PRRT (peptide receptor radionuclide therapy), the choice of second-line therapy is debatable. While GEP-NETs in children and adolescents are rare, the impact can be devastating. Advanced Accelerator Applications (AAA)/Novartis’s LUTATHERA is now the very first therapy approved specifically for use in pediatric patients with GEP-NETs. offering new hope to young patients living with this rare cancer. In January 2018, the FDA approved LUTATHERA, a radiolabeled somatostatin analog for the treatment of GEP-NETs. In April 2024, Novartis announced that the US FDA approved LUTATHERA for the treatment of pediatric patients 12 years and older with SSTR+ GEP-NETs, including foregut, midgut, and hindgut NETs. LUTATHERA is also approved in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs in adults, and in Japan for SSTR-positive NETs. All available therapies for NETs, whether monotherapy or combination, are currently leveraged to treat this complex, diverse population of patients, yet no treatment has maintained progression-free survival (PFS) indefinitely. At present, the NETs market is dominated by SSAs, however, by 2034, radioligand therapies are projected to capture the highest market share, reflecting a paradigm shift driven by their enhanced efficacy and the growing adoption of targeted treatment approaches. While LUTATHERA has primarily been used as a second-line treatment, there is a growing interest in expanding its use to first-line settings for medium- and high-risk NETs. This trend underscores the rising prominence of radioligand therapies in redefining treatment standards in the NETs space. Learn more about the market of NETs @ Neuroendocrine Tumors Treatment Neuroendocrine Tumors Emerging Drugs and Companies Some of the drugs in the pipeline include ITM-11 (ITM Isotope Technologies Munich), CABOMETYX (Exelixis/Ipsen/Takeda), CAM2029 (Camurus), AlphaMedix (Radiomedix/Orano Med), VMT- -NET (Perspective Therapeutics), and others. CABOMETYX (cabozantinib) is a small-molecule inhibitor targeting several receptor tyrosine kinases, such as VEGFRs, MET, RET, and the TAM family (TYRO3, MER, AXL). In August 2024, the FDA accepted a supplemental New Drug Application (sNDA) for cabozantinib to treat patients with advanced pancreatic neuroendocrine tumors (pNET) and extra-pancreatic neuroendocrine tumors (epNET) who have previously undergone treatment. The FDA set a PDUFA target date of April 3, 2025, for review and granted orphan drug designation for pNET. This application is supported by data from the Phase III CABINET trial, which studied CABOMETYX in these patient populations. ITM-11 (177Lu-edotreotide) , developed by ITM Isotope Technologies Munich , is a novel Targeted Radionuclide Therapy that combines two components: Edotreotide (DOTATOC), an octreotide-based somatostatin analog, and EndolucinBeta (n.c.a. lutetium-177 chloride), a low-energy beta-emitting synthetic radioisotope. It is currently under investigation in two Phase III clinical trials: COMPETE (NCT03049189) and COMPOSE (NCT04919226). COMPETE focuses on assessing ITM-11 for treating Grade 1 and Grade 2 GEP-NETs, while COMPOSE investigates its use in patients with well-differentiated high Grade 2 and Grade 3 GEP-NETs. ITM-11 was granted orphan designation for GEP-NET treatment based on Phase II data showing significant improvement in PFS. The other pipeline therapies for neuroendocrine tumors include RYZ101 (ACTINIUM-225 DOTATATE): BRISTOL MYERS SQUIBB/RAYZEBIO CAM2029: Camurus ALPHAMEDIX (212PB-DOTAMTATE): RADIOMEDIX/ORANO MED [212PB] VMT-α-NET: PERSPECTIVE THERAPEUTICS ELC-100 (ADVINCE): ELICERA THERAPEUTICS ONC201: CHIMERIX EO2401 + NIVOLUMAB: ENTEROME TIRAPAZAMINE (TEC-001): TECLISON It is more important than ever to ensure and understand supply chain and manufacturing issues of radiopharmaceuticals to stay at the forefront of radiopharmaceutical innovation, especially since a number of companies are investigating radiopharmaceuticals. Emerging key players should make sure that their product, supply, and production capabilities are adequate, and they should be prepared to meet the challenge of offering new therapeutic approaches to cancer patients who otherwise have limited options. In June 2024, BMS-RayzeBio was forced to pause a phase III trial due to an actinium shortage. Oncolytic virotherapy holds promise for cancer treatment. Oncolytic virotherapies like ELC100 (Elicera Therapeutics) and SVV-001 (Seneca therapeutics) are also being investigated for the treatment of NETs in early clinical trials. The anticipated launch of these emerging therapies are poised to transform the neuroendocrine tumors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the neuroendocrine tumors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about NETs clinical trials, visit @ Neuroendocrine Tumors Treatment Drugs Neuroendocrine Tumors Market Dynamics The neuroendocrine tumors market dynamics are anticipated to change in the coming years. NETs are often diagnosed at an early stage due to the hormonal symptoms they produce, allowing for timely intervention and better outcomes, and with advancements like LUTATHERA being the first therapy specifically approved for pediatric patients with GEP-NETs, along with continued research in targeted therapies such as somatostatin analogs and molecular inhibitors, there are growing opportunities for more effective and personalized treatments ; participation in clinical trials can further drive the discovery of new treatment modalities and improve patient outcomes. Furthermore, many potential therapies are being investigated for the treatment of NETs, and it is safe to predict that the treatment space will significantly impact the NETs market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the NETs market in the 6MM. However, several factors may impede the growth of the neuroendocrine tumors market. Since most of the NET cases comprise GEP-NETs, the lack of awareness among healthcare professionals and the general public often leads to delayed diagnosis and treatment . GEP-NETs are a heterogeneous group of tumors with diverse clinical presentations, making it difficult to develop standardized treatment protocols. Additionally, challenges in research and development , such as limited funding and resources, hinder advancements in the field, while the complexity of diagnosing GEP-NETs increases the risk of misdiagnosis or delayed diagnosis, resulting in suboptimal treatment outcomes. Moreover, neuroendocrine tumor treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the NETs market growth may be offset by failures and discontinuation of emerging therapies , unaffordable pricing , market access and reimbursement issues , and a shortage of healthcare specialists . Scope of the Neuroendocrine Tumors Market Report Neuroendocrine Tumors Therapeutic Assessment: Neuroendocrine Tumors current marketed and emerging therapies Neuroendocrine Tumors Market Dynamics: Conjoint Analysis of Emerging Neuroendocrine Tumors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL’s views, Analyst’s views, Neuroendocrine Tumors Market Access and Reimbursement Discover more about neuroendocrine tumor drugs in development @ Neuroendocrine Tumors Clinical Trials Table of Contents Related Reports Neuroendocrine Tumors Epidemiology Forecast Neuroendocrine Tumors Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted NETs epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan. Neuroendocrine Tumors Pipeline Neuroendocrine Tumors Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NETs companies, including RayzeBio, Inc., Seneca Therapeutics, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals, among others. Gastroenteropancreatic Neuroendocrine Tumors Market Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GEP-NET companies including Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limite, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, among others. Gastroenteropancreatic Neuroendocrine Tumors Pipeline Gastroenteropancreatic Neuroendocrine Tumors Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GEP-NET companies, including Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., Chimerix, among others. Pancreatic Neuroendocrine Tumors Market Pancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PNET companies including Novartis Pharmaceuticals, Pfizer, Keyrus Biopharma, Merck Sharp & Dohme LLC, Pfizer, Apices Soluciones S.L., Pharmacyclics LLC, Ipsen, among others. Oncology Conference Coverage Services DelveInsight’s Oncology Conference Coverage Services offer a thorough analysis of outcomes from major events like ASCO, ESMO, ASH, AACR, ASTRO, SOHO, SITC, the European CAR T-cell Meeting, and IASLC. This detailed examination provides businesses with essential insights for competitive intelligence and market trend forecasting, supporting the formulation of future strategies. Other Business Consulting Services Healthcare Competitive Intelligence Healthcare Licensing Services Healthcare Portfolio Management Case Study Learn how the engagement with respected KOLs bolstered the client's reputation as a leader in the pharma industry at KOL Profiling About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn | Facebook | Twitter
Bass 2-8 0-0 6, Okon 0-1 0-0 0, Hines 6-13 4-6 19, Knox 3-9 0-3 8, Madlock 7-14 2-4 17, Mack 6-9 0-0 18, Walker 2-7 2-2 8, Simpsom 0-2 0-0 0, Andrews 0-1 0-0 0, Fulcher 1-2 0-0 2, Kaego 0-0 0-0 0. Totals 27-66 8-15 78. Harris 2-8 0-0 5, Lyles 1-3 1-2 3, Gray 4-7 2-2 11, T.Johnson 3-10 0-0 8, N.Johnson 7-12 8-8 25, Scott 3-8 0-0 8, Hardman 6-7 1-2 19, Okonkwo 3-5 2-5 8, Young 3-8 4-4 10, Musiime-Kamali 0-1 0-0 0. Totals 32-69 18-23 97. Halftime_Akron 50-41. 3-Point Goals_Alabama St. 16-33 (Mack 6-9, Hines 3-5, Knox 2-4, Walker 2-4, Bass 2-7, Madlock 1-3, Simpsom 0-1), Akron 15-35 (Hardman 6-7, N.Johnson 3-5, Scott 2-5, T.Johnson 2-6, Gray 1-1, Harris 1-5, Lyles 0-2, Young 0-4). Rebounds_Alabama St. 25 (Madlock 5), Akron 49 (Harris, Okonkwo 10). Assists_Alabama St. 13 (Knox 4), Akron 21 (Harris, Gray, T.Johnson 4). Total Fouls_Alabama St. 19, Akron 14. A_1,589 (5,500).
MINNEAPOLIS — The brazen killing of UnitedHealthcare CEO Brian Thompson has captivated the nation this week, as authorities continue to search for the man who fatally shot the Maple Grove resident outside an investors’ meeting in Manhattan earlier this week. As of Friday afternoon, police were testing DNA from a water bottle and examining a fake New Jersey ID and a cellphone that may be connected to the suspect, the New York Times reported . Friday evening, investigators found a backpack in Central Park like the one that had been carried by the shooter, police said. According to the Times, it was unclear if the gun used in the shooting was found in the bag. Investigators believed the gun possibly was fitted with a suppressor, or might have been a veterinary gun used by farmers and ranchers to put down animals without making a loud sound. The FBI also announced Friday night a $50,000 reward for information leading to an arrest and conviction. Here’s what else we know about the case, the company and Thompson himself: No motive as manhunt continues Authorities continue searching for the man who shot and killed Thompson in Manhattan. They have not released a name or motive. The shooter approached Thompson from behind and fired several times before he fled into an alley nearby and then hopped on an e-bike and rode north to Central Park, police said. The day after Thompson’s death, Maple Grove police reported bomb threats against two homes the family owns in the city. Investigators on Thursday released photos that partly reveal the face of a person of interest in the case. Authorities found at least one bullet casing on the scene with the word “deny” on it, reviving criticism of a company and industry that became known for denying medical care claims. Minnesota health care companies step up security Minnetonka-based Medica temporarily closed its headquarters Friday amid a “general feeling of vulnerability and concern” as insurers faced mounting online vitriol in the wake of Thompson’s killing. UnitedHealth Group’s note of remorse about Thompson’s killing has attracted more than 83,000 laughing emoji reactions on Facebook. A spokesperson said the company’s offices will be closed through Dec. 13, citing safety concerns that sprang up following Wednesday’s shooting. Other insurers have taken similar steps to reduce the visibility of top executives. While Minneapolis-based UCare remains open, its front doors were locked Friday morning. “Of course Brian Thompson’s murder — and the ensuing vitriol on social media — sent shockwaves throughout our industry,” UCare said in a statement. “We have no reason to believe there is any danger specifically to our team. At the same time, there is a general feeling of vulnerability and concern.” Thompson’s killing has prompted companies, especially those in health care, across the country to step up security. “It’s a wake-up call for a lot of companies,” said Glen Kucera, the New York-based president of Enhanced Protection Services, an arm of security company Allied Universal. “Unfortunately, it sometimes takes an event like this to impact change in the threat landscape.” What we know about Brian Thompson Thompson lived in Maple Grove . His wife, Paulette, works as a physical therapist with HealthPartners. They have two teenage sons, 19 and 16. Thompson worked at UnitedHealthcare for 20 years and was named its CEO in 2021 . The Minnesota Star Tribune reported this year that Thompson was among the state’s top-paid executives with a total compensation of $9.1 million. Both Thompson and his wife graduated from the University of Iowa, where he got a bachelor’s degree in business administration in 1997. He graduated with special honors. While Thompson wasn’t well-known to his neighbors — one said he was “very quiet” and another said “no one really knew him” on the block — his killing shook co-workers and local business leaders. He was known as a champion for UnitedHealthcare’s support of the Special Olympics and an advocate for American Sign Language access across health care. “Brian was a principled leader and a true champion in the healthcare community,” Roberta Antoine Dressen, CEO of local trade group Medical Alley, said in a statement. UnitedHealthcare is one of Minnesota’s largest employers UnitedHealthcare is the largest insurer in the U.S. It’s owned by Minnetonka-based UnitedHealth Group, which employs more than 400,000 people. It’s Minnesota’s 10th-largest employer — approximately 19,000 of its employees are stationed here. The company has its roots in the development of the health maintenance organization model of health care pioneered by Dr. Paul Ellwood in the 1960s and ‘70s. UnitedHealthcare has been criticized by media and elected officials because of the way the company reviews and denies requests and claims for medical care. The U.S. Senate Permanent Subcommittee on Investigations announced in October that UnitedHealthcare and two other major Medicare insurers inflated profits by denying seniors stays in care facilities while they recovered from injuries and illnesses. The company went from denying 10.9% of cases in 2020 to 22.7% in 2022, according to a report from the subcommittee. Minnesota lawmakers barred UnitedHealthcare and other HMOs from the state’s Medicaid program earlier this year. ©2024 The Minnesota Star Tribune. Visit startribune.com . Distributed by Tribune Content Agency, LLC
None
STARTING GRID YOUR GUIDE TO THE WEEK ON THE NASCAR CIRCUIT It seems everyone except champion Joey Logano is eager to see to a change to the NASCAR playoff format. How to fix it remains up for debate. Logano won his third Cup Series championship earlier this month, re-igniting the conversation about whether the current playoff format is the best way to determine a worthy champion. Logano wound up winning four races this season, but only had 13 top 10 finishes in 37 races and clearly didn't have one of the best cars over the course of the season. Logano, it seemed, did just enough to get by. He got his share of breaks, too, using what amounted to a Hail Mary win in Nashville — stretching his empty fuel tank through five overtimes — to qualify for the postseason. He was actually eliminated from playoff contention in the second round, only to be reinstated after a competitor's car was ruled to be illegal. Logano's run to the title has left some drivers wanting to see the system altered, with suggestions ranging from minor tweaks to major changes. "I think the message we are trying to send is: Make the regular season matter more," said Denny Hamlin, driver of the No. 11 car for Joe Gibbs Racing and a co-owner of the 23XI Racing team. He suggested increasing the bonus points a driver gets during the regular season. "The (Christopher) Bells, (Kyle) Larsons, they deserve to have a really good buffer there to make it through the (playoff) rounds," Hamlin said. "We're in a sport where you can get caught up in so many wrecks and different things that can happen. ... There are 26 (regular season) races and they are proving to be not that substantial to winning a championship and that's not something you want." Hamlin suggested that over the past three years the Team Penske champions — Logano twice and Ryan Blaney once — "didn't have to do much" during the regular season. "And that's probably not good," Hamlin added. NASCAR likes the current playoff system because of the emphasis it places on each race heading down the final stretch of the season in its never-ending quest for Game 7 moments. Stock car racing's governing body remains open to tweaking the format — if it improves the sport. "I love that aspect of it," Bell said of the emphasis on the playoff races, "but maybe adjusting the points systems to make sure we get the right cars into the championship event would be awesome." Blaney said it's up to drivers to adapt the rules in place. But he said in his "ideal world" he'd like to see the top 16 drivers on points in the regular season qualify for the playoffs. He said race winners should get 10 or 15 points instead of five, and that the regular-season champion should get an additional 30 points. Blaney's final suggestion involves fewer elimination races. He suggested the 16-car field should be cut to eight after five playoff races, with the remaining eight drivers competing over the final five races for the championship. "I would like to see a group of races to end the year where you are not going to have anyone run away with it and you're going to have three to five races and you're still going to have some really good competition going on," Blaney said. Logano just shakes his head and offers a sarcastic smile at all the tweak talk. He was emphatic about the system not needing to be changed after his clinching win at Phoenix and didn't stray from that conviction at last Friday's annual awards ceremony in Charlotte. When asked if there are any changes that need to be made, Logano replied, "Nothing, personally. I wouldn't change a thing," adding that he thinks the format is "super entertaining." Of course, if you've won three championships since 2018, why would you want to change? "I think we all need to understand why we changed it in the first place, it's because the fans said they didn't like the way it was, so we changed it," Logano said. "And then everybody loved it. And it was great. And now, oh, we're going to complain about it again? C'mon, guys. Geez." Be the first to know Get local news delivered to your inbox!Texas Supreme Court overturns ruling that state Attorney General Ken Paxton testify in lawsuitInvesting in Kraken Stock | How to Buy Pre-IPO Shares
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Xiao-I To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Xiao-I as a result of purchasing (a) Xiao-I American depository shares (ADSs) issued in connection with the Company's initial public offering on or about March 9, 2023 and/or (b) Xiao-I securities between March 9, 2023 and July 12, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . [You may also click here for additional information] NEW YORK , Nov. 30, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against Xiao-I Corporation ("Xiao-I" or the "Company") (NASDAQ: AIXI ) and reminds investors of the December 16, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York , Pennsylvania , California and Georgia . The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com . As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that (1) Defendants had downplayed the true scope and severity of risks that Xiao-I faced due to certain of its Chinese shareholders' non-compliance with Circular 37 Registration, including the Company's inability to use Offering proceeds for intended business purposes; (2) Xiao-I failed to comply with GAAP in preparing its financial statements; (3) Defendants overstated Xiao-I's efforts to remediate material weaknesses in the Company's financial controls; (4) Xiao-I was forced to incur significant R&D expenses to effectively compete in the AI industry; (5) Xiao-I downplayed the significant negative impact that such expenses would have on the Company's business and financial results; (6) accordingly, Xiao-I overstated its AI capabilities, R&D resources, and overall ability to compete in the AI market; (7) as a result of all the foregoing, there was a substantial likelihood that Xiao-I would fail to comply with the NASDAQ's Minimum Bid Price Requirement; and (8) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein. On or around March 8, 2023 , Xiao-I launched its initial public offering (IPO), selling 5.7 million American depositary shares (ADSs) at $6.80 each. Since the IPO, the price of Xiao-I's ADSs has dropped significantly, causing losses for investors. On August 10, 2023 , Xiao-I Corporation filed with the U.S. Securities and Exchange Commission its amended annual report for the year ended December 31, 2022 on Form 10-K/A. In the amended annual report, Xiao-I disclosed that "However, should there be any changes to PRC laws and regulations or internal control policies of Bank of Ningbo in the future, [Zhizhen Artificial Technology ( Shanghai ) Company Limited, a Company subsidiary] then may be restricted from transferring funds from overseas to its capital account with Bank of Ningbo as a result." On this news, the price of Xiao-I American Depositary Shares ("ADSs") fell $0.93 per ADS, or 11.56%, to close at $7.11 on August 11, 2023 . On July 15, 2024 , Xiao-I issued a press release announcing "that it received a notification letter dated July 11, 2024 (the 'Deficiency Letter') from the Listing Qualifications Department of [t]he [NASDAQ], indicating that the Company is no longer in compliance with the minimum bid price requirement as set forth in Nasdaq Listing Rule 5450(a)(1) as the Company's closing bid price per [ADS] . . . has been below $1.00 for a period of 30 consecutive business days." On this news, Xiao-I's ADS price fell 2.28% to close at approximately $0.67 per ADS on July 15, 2024 . The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Xiao-I's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Xiao-I Corporation class action, go to www.faruqilaw.com/AIXI or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . Follow us for updates on LinkedIn , on X , or on Facebook . Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. SOURCE Faruqi & Faruqi, LLPTwo awards for private hire firm which operates in Gwent
Soccer-Arsenal thump West Ham to go second, Kluivert bags penalty hat-trick for BournemouthBarry Keoghan shares impact Sabrina Carpenter cheating rumours have on his young son's life
Conference title games a chance at a banner, bragging rights and, for some, a season-wrecking lossWashington Capitals star Alex Ovechkin has a broken left fibula and is expected to miss 4 to 6 weeks